Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dolby Laboratories, Inc. (DLB) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Dolby Laboratories, Inc.Trade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Dolby Laboratories, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? Dolby Laboratories, Inc. trades at $60.91 (market cap $5.75B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 14.3× Dolby Laboratories, Inc.'s market cap, and Dolby Laboratories, Inc. pays the higher dividend (2.35%). Which is the better fit depends on your goals.

DLBREGN
Market Cap
$5.75B$82.06B
Sector
IndustrialsHealth
52-Week High
$75.62$812.27
52-Week Low
$48.51$555.51
Enterprise Value
$5.12B$76.77B
Dividend Yield
2.35%0.47%

Returns comparison

Trailing returns across standard periods

About Dolby Laboratories, Inc.

Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.

Read more on DLB

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN